C-reactive protein as biomarker for immune-related adverse events in melanoma patients treated with immune checkpoint inhibitors in the adjuvant setting

Research output: Contribution to journalMeeting abstract (Journal)

Original languageEnglish
Pages (from-to)S759-S759
JournalAnnals of Oncology
Volume31
DOIs
Publication statusPublished - Sep 2020
EventESMO Virtual Congress -
Duration: 19 Sep 202018 Oct 2020

Keywords

  • C-reactive protein
  • Biomarker
  • melanoma

Cite this